SMA
VRTX icon

Sage Mountain Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Sage Mountain Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,997
Closed -$905K – 554
2025
Q4 		$905K Sell
1,997
-11
-0.5% -$4.74K 0.05% 179
2025
Q3 		$786K Buy
2,008
+603
+43% +$252K 0.05% 198
2025
Q2 		$625K Buy
1,405
+163
+13% +$75.1K 0.04% 205
2025
Q1 		$602K Sell
1,242
-63
-5% -$29.4K 0.04% 191
2024
Q4 		$526K Buy
1,305
+146
+13% +$67.7K 0.04% 201
2024
Q3 		$539K Sell
1,159
-3
-0.3% -$1.44K 0.05% 189
2024
Q2 		$545K Buy
1,162
+421
+57% +$183K 0.05% 168
2024
Q1 		$310K Buy
741
+63
+9% +$26.6K 0.03% 233
2023
Q4 		$276K Buy
678
+14
+2% +$5.17K 0.03% 217
2023
Q3 		$231K Buy
664
+45
+7% +$15.7K 0.03% 219
2023
Q2 		$218K Buy
+619
New +$209K 0.03% 236

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sage Mountain Advisors's VRTX Position: Q1 2026 in Review

Sage Mountain Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 1,997 shares — an estimated $905K sold.

Sage Mountain Advisors first reported a position in VRTX in Q2 2023 and held it in 11 quarters. The position peaked at $905K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Sage Mountain Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Sage Mountain Advisors sold 1,997 Vertex Pharmaceuticals shares in Q1 2026, an estimated $905K.
  • Sage Mountain Advisors first reported a position in Vertex Pharmaceuticals in Q2 2023 and held it in 11 quarters.
  • Sage Mountain Advisors's Vertex Pharmaceuticals position peaked at $905K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sage Mountain Advisors's 13F filing for Q1 2026, filed 11 May 2026.